ArticleAmerican journal of obstetrics and gynecology2011
Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast.
Article in American journal of obstetrics and gynecology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 115 citations in OpenAlex.
- Article
- Integrative multi-omic analysis reveals potential biomarkers in the cervicovaginal fluid of patients with placenta accrete spectrum.BMC pregnancy and childbirth · 2024Article
- Evaluation of maternal serum protein biomarkers in the prenatal evaluation of placenta accreta spectrum: A systematic scoping review.Acta obstetricia et gynecologica Scandinavica · 2024Article
- Prophylactic occlusion balloons of both internal iliac arteries in caesarean hysterectomy for placenta accreta spectrum disorder reduces blood loss: A retrospective comparative study.European journal of obstetrics & gynecology and reproductive biology: X · 2024Article
- Diagnostic Role of Cell-Free miRNAs in Identifying Placenta Accreta Spectrum during First-Trimester Screening.International journal of molecular sciences · 2024Article
- Placenta Accreta Spectrum Diagnosis Challenges and Controversies in Current Obstetrics: A Review.International journal of women's health · 2023Review
- (Dis)similarities between the Decidual and Tumor Microenvironment.Biomedicines · 2022Review
- Clinical value of serum VEGF and sFlt-1 in pernicious placenta previa.Annals of medicine · 2021Article
- Placenta percreta presenting as uterine rupture following previous B-Lynch suture.BMJ case reports · 2021Article
- Maternal Serum VEGF Predicts Abnormally Invasive Placenta Better than NT-proBNP: a Multicenter Case-Control Study.Reproductive sciences (Thousand Oaks, Calif.) · 2021Article
- The BMP2 Signaling Axis Promotes Invasive Differentiation of Human Trophoblasts.Frontiers in cell and developmental biology · 2021Article
- The Risk of Postpartum Hemorrhage Following Prior Prelabor Cesarean Delivery Stratified by Abnormal Placentation: A Multicenter Historical Cohort Study.Frontiers in medicine · 2021Article
- Soluble FMS-Like Tyrosine Kinase-1: Role in placenta accreta spectrum disorder.F1000Research · 2021Article
- Review
- Integrative analysis provides multi-omics evidence for the pathogenesis of placenta percreta.Journal of cellular and molecular medicine · 2020Article
- Development and validation of a four-microRNA signature for placenta accreta spectrum: an integrated competing endogenous RNA network analysis.Annals of translational medicine · 2020Article
- The expression and biological function of chemokine CXCL12 and receptor CXCR4/CXCR7 in placenta accreta spectrum disorders.Journal of cellular and molecular medicine · 2020Article
- Biomarkers of abnormally invasive placenta.Placenta · 2020Article
- Associations between metal concentrations in whole blood and placenta previa and placenta accreta: the Japan Environment and Children's Study (JECS).Environmental health and preventive medicine · 2019Article
- Serum Angiogenic and Anti-angiogenic Markers in Pregnant Women with Placenta Percreta.Balkan medical journal · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
objectiveWe sought to characterize serum angiogenic factor profile of women with complete placenta previa and determine if invasive trophoblast differentiation characteristic of accreta, increta, or percreta shares features of epithelial-to-mesenchymal transition. STUDY
designWe analyzed gestational age-matched serum samples from 90 pregnant women with either complete placenta previa (n = 45) or uncomplicated pregnancies (n = 45). Vascular endothelial growth factor (VEGF), placental growth factor, and soluble form of fms-like-tyrosine-kinase-1 were immunoassayed. VEGF and phosphotyrosine immunoreactivity was surveyed in histological specimens relative to expression of vimentin and cytokeratin-7.
resultsWomen with previa and invasive placentation (accreta, n = 5; increta, n = 6; percreta, n = 2) had lower systemic VEGF (invasive previa: median 0.8 [0.02-3.4] vs control 6.5 [2.7-10.5] pg/mL, P = .02). VEGF and phosphotyrosine immunostaining predominated in the invasive extravillous trophoblasts that coexpressed vimentin and cytokeratin-7, an epithelial-to-mesenchymal transition feature and tumorlike cell phenotype.
conclusionLower systemic free VEGF and a switch of the interstitial extravillous trophoblasts to a metastable cell phenotype characterize placenta previa with excessive myometrial invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.